louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03277612: Effects of C-section Delivery on Infant Brain Development
Official title: Effects of C-section Delivery on Infant Brain Development
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Healthy
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2017-09-11
Enrollment: 9
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy women and their unborn child

Brief summary: The study will help investigators learn more about whether different delivery modes influence infant's brain development

Detailed description: For this study, the investigators are enrolling women who are pregnant with their second child who are planning to have a planned C-section or a spontaneous vaginal birth after C-section. The investigators will see the pregnant mom at 36 weeks pregnant and then have the mom and the baby return for a visit at 2 weeks postnatal.

Eligibility criteria: Inclusion Criteria:

* Conceived without fertility treatments
* Singleton pregnancy recruited at or before 36 weeks of gestation
* Second parity with planned repeated C-section delivery or with planned spontaneous vaginal delivery after C-section.

Exclusion Criteria:

* Preexisting medical conditions
* Sexually transmitted diseases
* Medical complications developed during pregnancy
* Medical complications developed during labor and delivery
* Emergency c-section delivery
* Infants born preterm or post-term
* Infants needing mechanical ventilation, have congenital abnormalities, birth defects, intrauterine growth restriction, low Apgar score (\<7), or other medical issues developed at birth or before 2 weeks of age affecting the outcome of interest as determined by the PI.

Primary outcomes:
measure: Gut Microbiome and how it effects Brain Structure
timeFrame: up to 2 weeks
measure: Gut Microbiome and how it effects brain function
timeFrame: up to 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
affiliation: Arkansas Children's Nutrition Center
name: Xiawei Ou, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02969746: Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
Official title: Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Anticoagulants; Circulating, Hemorrhagic Disorder
Keywords: activated charcoal, direct oral anticoagulant
Lead sponsor: University Hospital, Angers
Sponsor class: OTHER_GOV
First posted: 2016-11-21
Enrollment: 140
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a prospective, multicentric, randomized, open labeled superiority trial

This study aims to evaluate the efficacy of oral activated charcoal for improving elimination of direct oral anticoagulants ( Rivaroxaban, Apixaban) in case of an unscheduled invasive procedure delayed to this anticoagulant treatment.

The primary outcome is the anticoagulant's half life. Plasma concentration will be measured by liquid chromatography-mass spectrometry for the main analysis (pharmacokinetic).

A total of 140 patients will randomly be assigned to the charcoal or control group, stratified according to their anticoagulant drug.


Eligibility criteria: Inclusion Criteria:

* Patients under direct oral anticoagulant treatment (Apixaban, Rivaroxaban or Dabigatran)
* Age ≥18 years;
* Clinical condition needing a surgery or invasive procedure ( lumbar puncture, biopsy...), needing anticoagulant treatment interruption and intervention to be postponed
* Signed informed consent

Exclusion Criteria:

* Urgent immediate surgery without any possibility to wait for 24 hours
* contraindication for receiving oral treatment
* Active uncontrolled bleeding or bleeding in critical organ
* Hemodynamic instability, shock
* Known anticoagulant concentration \< 50ng/mL
* drug intoxication
* Fructose intolerance, glucose and galactose malabsorption syndrome, sucrase-isomaltase deficit
* Treated epileptic disease
* Pregnant or breast feeding
* Patient under guardianship
* No insurance cover
* Patient unable to give his consent
* Participation to another therapeutic trial

Primary outcomes:
measure: Direct Oral Anticoagulant half life
timeFrame: 0 to 8 hours
Secondary outcomes:
measure: Time to obtain a plasmatic concentration lower than 50ng/mL
timeFrame: 0 to 8 hours
measure: Rate of bleeding and/or thromboembolic complications after activated charcoal administration or not.
timeFrame: until Day 7
measure: Number of patients with adverse events.
timeFrame: day 7
Other outcomes:
Locations:
city: Angers
country: France
facility: Chu Angers
city: Angers
country: France
facility: Chu Angers
city: Cleron
country: France
facility: CHU Clermont-ferrand
city: Le Mans
country: France
facility: CH Le MANS
city: Poitiers
country: France
facility: CHU de Poitiers
city: Saint Etienne
country: France
facility: CHU de St Etienne
Study officials:
affiliation: Sponsor GmbH
name: Thomas Moumneh, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06725446: Uterine Niche Symptoms and US and Hystroscopic Findings
Official title: Correlation Between Symptoms and Hystroscopic Findings in Patients with Uterine Niche: Cross-sectional Study.
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Uterine Niche
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-12-10
Enrollment: 70
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: patients with abnormal uterine bleeding previous cs

Brief summary: correlation between clinical ,soonographic and hysteroscopic findings in patients with uterine niche


Eligibility criteria: Inclusion Criteria:

* patient with uterine niche previous cs

Exclusion Criteria:

abnormal uterine bleeding

-

Primary outcomes:
measure: uterine niche symptoms and Hystroscopic and US findings
timeFrame: 2023-2025
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Assiut University
Study officials:
References:
Clinical trial NCT00394446: Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors
Official title: Phase I Open Label, Dose Escalating, Multiple Dose Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of MPC-6827 Administered IV Weekly X 3, Repeated Every 28 Days, in Subjects With Refractory Solid Tumors.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Refractory Solid Tumors
Keywords: Solid Tumors
Refractory
Brain
Lead sponsor: Myrexis Inc.
Sponsor class: INDUSTRY
First posted: 2006-11-01
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Phase 1, Multiple Dose Study of MPC-6827 in Subjects with Refractory Solid Tumors.


Eligibility criteria: Inclusion Criteria:

1. Advanced or Metastatic Cancer
2. Measurable / Evaluable Disease
3. Karnofsky score greater than or equal to 70%
4. Adequate Hematology / Organ function
5. No Baseline peripheral or central neuropathy above grade 1

Exclusion Criteria:

1. Hypersensitivity to Cremophor EL
2. Pregnant or Lactating
3. Spinal Cord Compression
4. Pre-existing Dementia / Cognitive Disfunction
5. Require Neupogen or Neulasta to Maintain Neutrophil Count
6. Have Primary Brain Cancer
7. Have history of Ischemic Heart Disease
8. Have Diabetes

Primary outcomes:
measure: Maximum Tolerated Dose
timeFrame: 1 year
measure: Pharmacokinetics
timeFrame: 22 months
Secondary outcomes:
measure: Antitumor Activity
timeFrame: 2 years
Other outcomes:
Locations:
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute at the University of Utah
state: Utah
Study officials:
affiliation: Myrexis Inc.
name: Margaret Yu, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00373646: Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Official title: Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: MALT Lymphoma
Keywords: MALT Lymphoma
thalidomide
disseminated MALT Lymphoma or at relapse following HP-eradication
or chemotherapy or radiation
Lead sponsor: Medical University of Vienna
Sponsor class: OTHER
First posted: 2006-09-08
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.

Detailed description: The objectives of this study are to evaluate the effectivity and the safety of thalidomide in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation. It is a phase II prospective single arm study with a target sample size of 16 patients. Thalidomide is given orally at an initial dose of 100 mg for a maximum duration of 6 months.

Eligibility criteria: Inclusion Criteria:

* Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV)
* With first or greater relapse after HP-eradication, radiation or chemotherapy
* Age \> 18
* Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
* ECOG status _\< 2
* Must be capable of understanding the purpose of the study and have given written informed consent

Primary outcomes:
measure: To evaluate the clinical potential of thalidomide to induce objective/histologic responses in patients with MALT lymphoma
timeFrame: 6 months
Secondary outcomes:
measure: To evaluate the safety of thalidomide in this patient population and to evaluate
timeFrame: 6 months
measure: The impact of thalidomide on progression free survival
timeFrame: 12 months
Other outcomes:
Locations:
city: Vienna
country: Austria
facility: Department of Internal Medicine I
Study officials:
affiliation: Department of Internal Medicine I
name: Markus Raderer, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05045846: Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection.
Official title: Diagnostic Accuracy of Rapid Antigen Test Based on Anterior Nasal Swab Compared With RT-PCR for SARS-CoV-2 Detection.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid19
Keywords: rapid antigen test
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
First posted: 2021-09-16
Enrollment: 3461
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The infection pressure in the Capital Region of Denmark including Testcenter Taastrup was below 1.0%, throughout the study period

Brief summary: The aim of this study was to determine the accuracy of anterior nasal swab in rapid antigen (Ag)-tests in a low SARS-CoV-2 prevalence and massive screened community.


Eligibility criteria: Inclusion Criteria:

* Citizens, above 18 years of age, who had self-booked an appointment for COVID-19 test at Testcenter Taastrup, Copenhagen, Denmark, in the period of 2nd of March to 22nd of March were offered to participate in the project

Exclusion Criteria:

* Patients referred to COVID-19 testing by a doctor with symptoms of COVID-19 were tested in a separate section of the test centers and are not included in this study

Primary outcomes:
measure: Accuracy of anterior nasal swab in rapid antigen (Ag)-tests
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Christian von Buchwald, MD, DMSc, Professor
Study officials:
References:
Clinical trial NCT04654910: PROMIS and Patient Satisfaction
Official title: Does Patient-Reported Outcome Measure Use in Clinic Visits Improve Patient Satisfaction and Experience? A Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ankle Pathology
Foot Pathology
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: American Orthopaedic Foot and Ankle Society
First posted: 2020-12-04
Enrollment: 275
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The primary aim for this study is to determine if patient satisfaction and experience is improved with the active discussion/inclusion of PROMIS scores during new foot and ankle clinic patient visits.


Eligibility criteria: Inclusion

* Patients over the age of 18
* New patient at the foot and ankle clinic

Exclusion

* Patients under the age of 18
* Patients presenting for a Follow up visit

Primary outcomes:
measure: mean pain interference domain measured by PROMIS
timeFrame: baseline, before intervention
measure: mean Patient Activation Measure (PAM)
timeFrame: baseline, after intervention
measure: percent of participant who respond favorably on the Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS)
timeFrame: baseline, after intervention
measure: mean depression
timeFrame: baseline, before intervention
measure: mean physical function
timeFrame: baseline, before intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester Medical Center
state: New York
Study officials:
References:
Clinical trial NCT01382810: Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms
Official title: A Randomized Masked Evaluation of Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Dry Eye Syndromes
Keywords: dry eye signs and symptoms
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2011-06-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate and compare the effects of Altaire Gel forming solution and Refresh Tears in mild-moderate dry eye patients.


Eligibility criteria: Inclusion Criteria:

* Patients 18 years or older.
* Males or females.
* Patient reported dry eye symptoms (episodic, annoying, activity limiting).
* Physician assessment of mild-moderate dry eye.
* Patient willing to instill drops TID and complete entire length of protocol.
* TBUT _\< 10 seconds.
* At least Grade 6 Corneal Staining.

Exclusion Criteria:

* Current topical cyclosporine use (Restasis)
* Current Refresh use.
* Refractive surgery within the last 6 months.
* Oral or topical corticosteroid use.
* Severe dry eye patients by physician assessment.
* Current active blepharitis.
* Oral doxycycline use.
* Oral antihistamine use.

Primary outcomes:
measure: TBUT
timeFrame: 2 months
measure: Conjunctival and Corneal staining
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Lake Villa
country: United States
facility: Jackson Eye, SC
state: Illinois
city: Warwick
country: United States
facility: Koch Eye Associates
state: Rhode Island
Study officials:
References:
Clinical trial NCT03171610: Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy
Official title: Randomized Double-blind Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patients Undergoing Laparoscopic Nephrectomy
Keywords: laparoscopic nephrectomy
Patient-controlled analgesia (PCA)
sufentanil
fentanyl
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2017-05-31
Enrollment: 82
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare the efficacy of iv PCA with fentanyl or sufentanil in patients undergoing laparoscopic nephrectomy


Eligibility criteria: Inclusion Criteria:

1. patients undergoing laparoscopic or robot-assisted laparoscopic nephrectomy (total or partial)
2. patient who want intravenous PCA for postoperative pain control

Exclusion Criteria:

1. long-term use of opioid, pain reliever or tranquilizers
2. a history of DM neuritis
3. prolonged prothrombin time or activated partial thromboplastin time
4. impairment of cognitive function
5. obesity (BMI ≥ BMI 30 kg/m2)

Primary outcomes:
measure: Efficacy of iv PCA with fentanyl or sufentanil in patients undergoing laparoscopic nephrectomy: Incidence of postoperative nausea and vomiting (PONV)
timeFrame: 24 hrs after recovery room discharge
Secondary outcomes:
measure: postoperative pain score
timeFrame: at arrival to recovery room, 30 minutes after arrival to recovery room, 1 hour after recovery room discharge, 6 hrs after recovery room discharge, 24 hrs after recovery room discharge
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea
Study officials:
References:
Clinical trial NCT06409910: ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY (AMPORA)
Official title: A Phase II Randomized Trial: ALTERNATE DAY ULTRAHYPOFRACTIONATED OR DAILY MODERATELY HYPOFRACTIONATED POST OPERATIVE RADIOTHERAPY
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Post-Operative Prostate Cancer
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2024-05-10
Enrollment: 204
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Arm 1: External beam radiotherapy 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily.

Arm 2: External beam radiotherapy 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.
Primary purpose: TREATMENT

Brief summary: This is a multi-institution, randomized, non-inferiority Phase II trial comparing external beam radiotherapy delivered as 54 Gy in 20 fractions to prostate bed +/- 44 Gy in 20 fractions to pelvic lymph nodes delivered daily with external beam radiotherapy delivered as 30 Gy in 5 fractions to prostate bed +/- 25 Gy in 5 fractions to pelvic lymph nodes delivered on alternate days.


Eligibility criteria: Inclusion Criteria:

1. Age \> 18 years
2. Able to provide informed consent
3. Histologic diagnosis of prostate adenocarcinoma
4. ECOG performance status 0-1
5. Previous radical prostatectomy \> 6 months prior to radiotherapy start date
6. Planned to receive post-operative radiation

Exclusion Criteria:

1. Prior pelvic radiotherapy
2. Contraindications to radiotherapy
3. Mets confirmed as per (if scan has been done for clinical care)
4. Participants with visible disease in the prostate bed or pelvic lymph nodes on imaging are not eligible for treatment on study.

Primary outcomes:
measure: Rates of Acute Toxicity
timeFrame: 2 years
Secondary outcomes:
measure: Rates of Acute and Late Toxicity
timeFrame: 2 years
measure: Quality of Life Outcomes
timeFrame: 2 years
measure: Quality of Life Outcomes
timeFrame: 2 years
measure: Biochemical disease-free survival
timeFrame: 2 years
measure: Disease Control Rate
timeFrame: 2 years
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network - Princess Margaret Cancer Centre
state: Ontario
Study officials:
References:
Clinical trial NCT01488110: Investigation of Efficacy and Outcome of a New Medical Device for Treatment of Migraine
Official title: Undersökning av ny Behandlingsmetod Vid migränanfall (Evaluation of a New Treatment for Migraine Attacks)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Migraine
Lead sponsor: Karolinska University Hospital
Sponsor class: OTHER
First posted: 2011-12-08
Enrollment: 40
Sex: ALL
Minimum age (years): 20
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect two months post treatment. Another purpose is to investigate if and how this treatment affects manifestations of the autonomic nervous system activity.


Eligibility criteria: Inclusion Criteria:

* Female or male subjects, in otherwise good health, 20 to 55 years of age
* Subjects who meet the ICHD-2 (2nd Edition of The International Headache Classification) criteria for migraine headache
* Subjects with a minimum of 1 migraine attack per month
* Attack duration of 4 to 72 hours
* Normal attack intensity of at least 4 on a 0-10 VAS-scale

Exclusion Criteria:

* Completed heart surgery
* Cardiovascular diseases
* Vascular damages on neck vessels
* Diseases other than migraine of the CNS
* Severe disease of vital body organs
* Severe psychiatric disorders
* More than 6 migraine attacks per month

Primary outcomes:
measure: Change from baseline in pain intensity according to VAS-scales (0-10)
timeFrame: Estimation 40 minutes
Secondary outcomes:
measure: RR (Heart rate)-interval
timeFrame: Estimation 40 minutes
measure: Change from baseline in sympathetic nervous system activity
timeFrame: Estimation 40 minutes
measure: Blood pressure
timeFrame: Estimation 40 minutes
measure: Change from baseline in attack frequency based on completed patient diaries
timeFrame: 3 to 4 months
measure: Change from baseline in attack intensity based on completed patient diaries
timeFrame: 3 to 4 months
measure: Change from baseline in attack duration based on completed patient diaries
timeFrame: 3 to 4 months
measure: Change from baseline in medicine consumption based on completed patient diaries
timeFrame: 3 to 4 months
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: Karolinska University Hospital, Huddinge
Study officials:
affiliation: Karolinska University Hospital
name: Juto
role: PRINCIPAL_INVESTIGATOR
References: